Literature DB >> 15955469

Cardiovascular risk factors and metabolic control in type 2 diabetic subjects attending outpatient clinics in Italy: the SFIDA (survey of risk factors in Italian diabetic subjects by AMD) study.

Marco Comaschi1, Carlo Coscelli, Domenico Cucinotta, Pierluigi Malini, Enzo Manzato, Antonio Nicolucci.   

Abstract

BACKGROUND AND AIM: To perform an observational, cross-sectional study aiming to assess multiple cardiovascular risk factors and metabolic control in a very large and representative sample of type 2 diabetic subjects attending diabetes outpatient clinics (DOCs) in Italy. METHODS AND
RESULTS: Two hundred and sixty-one clinics were involved, representing about one-third of the whole number of DOCs in the Country. Each clinic recruited on a random basis from 50 to 100 type 2 diabetic patients aged 35-70 years, diagnosed more than six months before the start of the study. Demographic and clinical data were collected and blood pressure, lipids, HbA(1c), fasting blood glucose (FBG), and microalbuminuria were measured. Overall, 12,222 type 2 diabetic patients were recruited in 253 DOCs. Female subjects showed higher FBG, HbA 1c, blood pressure, lipid levels, and a longer duration of disease. The proportion of patients with BMI > or = 30 was 33.3% among males and 45.9% among females; 40.9% of male patients had a waist circumference greater than 102 cm, while 79% of female patients had a waist circumference over 88 cm. More than two-third of the patients (74.4%) had systolic blood pressure values of > or = 130 mmHg, and one-third (33.2%) had diastolic values > or = 85 mmHg. The mean value of HbA(1c) was 7.6+/-1.6, and 23.7% of the observed population had an HbA 1c level > 8.5%. More than half of the study population had total cholesterol levels > or = 5.2 mmol/l, 47% had LDL cholesterol values of 3.3 mmol/l or greater and 9.6% had HDL cholesterol level lower than 0.90 mmol/l. The presence of multiple lipid alterations was associated with markedly higher HbA 1c levels, in both subjects treated with lipid lowering drugs and untreated subjects. Finally, even moderate increases in HbA 1c levels (i.e. HbA 1c > 7.5%) were associated with a statistically significant greater risk of systolic blood pressure levels > or = 160 mmHg in women (OR = 1.40; 95% CI 1.09-1.80) but not in men (OR = 1.21; 95% CI 0.96-1.54).
CONCLUSIONS: The SFIDA study provides a clear indication of the need to orient diabetes care towards the control of global cardiovascular risk. Only a stricter adherence to the existing guidelines and a much stronger attention to the attainment of the desired therapeutic goals will allow a decrease in morbidity and mortality as well as in the costs related to diabetes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15955469     DOI: 10.1016/j.numecd.2004.07.003

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  12 in total

1.  A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide.

Authors:  Matthew R Weir; Willa A Hsueh; Shawna D Nesbitt; Thomas J Littlejohn; Alan Graff; Ali Shojaee; William F Waverczak; Chunlin Qian; Christopher J Jones; Joel M Neutel
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-02-05       Impact factor: 3.738

2.  Quality of diabetes care predicts the development of cardiovascular events: results of the AMD-QUASAR study.

Authors:  Maria C E Rossi; Giuseppe Lucisano; Marco Comaschi; Carlo Coscelli; Domenico Cucinotta; Patrizia Di Blasi; Giovanni Bader; Fabio Pellegrini; Umberto Valentini; Giacomo Vespasiani; Antonio Nicolucci
Journal:  Diabetes Care       Date:  2011-02       Impact factor: 19.112

3.  Therapeutic target achievement in type 2 diabetic patients after hyperglycemia, hypertension, dyslipidemia management.

Authors:  Ah Young Kang; Su Kyung Park; So Young Park; Hye Jeong Lee; Ying Han; Sa Ra Lee; Sung Hwan Suh; Duk Kyu Kim; Mi Kyoung Park
Journal:  Diabetes Metab J       Date:  2011-06-30       Impact factor: 5.376

4.  Hypertension and type 2 diabetes: a cross-sectional study in Morocco (EPIDIAM Study).

Authors:  Mohamed Berraho; Youness El Achhab; Abdelilah Benslimane; Karima El Rhazi; Mohamed Chikri; Chakib Nejjari
Journal:  Pan Afr Med J       Date:  2012-03-20

Review 5.  Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review.

Authors:  Ann D Colosia; Roberto Palencia; Shahnaz Khan
Journal:  Diabetes Metab Syndr Obes       Date:  2013-09-17       Impact factor: 3.168

6.  Differences in the Cardiometabolic Control in Type 2 Diabetes according to Gender and the Presence of Cardiovascular Disease: Results from the eControl Study.

Authors:  Josep Franch-Nadal; Manel Mata-Cases; Irene Vinagre; Flor Patitucci; Eduard Hermosilla; Aina Casellas; Bonaventura Bolivar; Dídac Mauricio
Journal:  Int J Endocrinol       Date:  2014-09-21       Impact factor: 3.257

7.  Management of hypertension and diabetes mellitus by cardiovascular and endocrine physicians: a China registry.

Authors:  Jie Song; Chang-Sheng Sheng; Qi-Fang Huang; Li-Hua Li; Chang-Sheng Ma; Xiao-Hui Guo; Li-Nong Ji; Ji-Guang Wang
Journal:  J Hypertens       Date:  2016-08       Impact factor: 4.844

8.  Trends in medical performance in diabetic patients in primary care clinics compared with those in hospitals: Shiga Diabetes Clinical Survey, Japan, 2000-2012.

Authors:  Itsuko Miyazawa; Aya Kadota; Motozumi Okamoto; Katsuyuki Miura; Hiroshi Maegawa; Atsuo Ohnishi
Journal:  Diabetol Int       Date:  2016-07-26

9.  Achievement of cardiometabolic goals among diabetic patients in Spain. A nationwide population-based study.

Authors:  Beatriz Navarro-Vidal; José R Banegas; Luz M León-Muñoz; Fernando Rodríguez-Artalejo; Auxiliadora Graciani
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.240

10.  Hypertension among 1000 patients with type 2 diabetes attending a national diabetes center in Jordan.

Authors:  Fayzeh M Mubarak; Erika S Froelicher; Hashem Y Jaddou; Kamel M Ajlouni
Journal:  Ann Saudi Med       Date:  2008 Sep-Oct       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.